Sklamberg Clarifies Misconceptions About Biden's Marijuana Policy

Life Sciences & Healthcare Regulatory partner Howard Sklamberg was recently featured in the POLITICO article “Why Fears About Biden’s Marijuana Moves Are Overblown.”

In the extensive Q&A, Sklamberg, a former high-ranking FDA official, discussed the potential impact of the Biden administration's move to reclassify marijuana under federal drug policy and addressed concerns from legalization advocates about this policy shift. He shared insights on the myths surrounding the rescheduling's impact on state cannabis programs and the pharmaceutical industry's involvement.

Sklamberg also highlighted the improbability of increased enforcement following reclassification, noting that "If you're going to launch an enforcement initiative against cannabis, why would you start off with saying, ‘Oh, by the way, it's less of a risk than we thought," and pointed out the limited resources of the FDA for cannabis enforcement.

Read the full article (subscription required).